Skip to main content
SpringerLink
Log in

Selective Inhibitors of Cyclooxygenase-2

Potential in Elderly Patients

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively used as antiinflammatory and analgesic agents in the elderly, as well as for their antithrombotic properties. In the future, NSAIDs may be more widely used in this sector of the population for the prevention of colon cancer. However, the elderly demonstrate a particularly high incidence of adverse reactions to this class of compounds. The factors responsible for this differential toxicity involve age-related pharmacokinetic, pharmacodynamic and physiological factors, as well as coincident disease states and polypharmacy.

Selective inhibitors of cyclooxygenase-2 form a novel class of antiinflammatory drugs that, in animal studies, exhibit significantly fewer adverse effects on the gastrointestinal tract than standard NSAIDs. If this proves to be the case in humans, these novel agents may be useful for the treatment of inflammation and pain as well as in colorectal cancer prevention, but they will not have utility as antithrombotic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wood PHN, Bradley EM. An epidemiological appraisal of bone and joint disease in the elderly. In: Wright V, editor. Bone and joint disease in the elderly. Edinburgh: Churchill Livingstone, 1982: 1–27

    Google Scholar 

  2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94

    CAS  PubMed  Google Scholar 

  3. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9

    Google Scholar 

  4. Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989; 37: 549–55

    CAS  PubMed  Google Scholar 

  5. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11

    CAS  PubMed  Google Scholar 

  6. Greenwald P. Colon cancer overview. Cancer 1992; 70: 1206–15

    CAS  PubMed  Google Scholar 

  7. Koutsos MI, Shiff SJ, Rigas B. Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk patients? Drugs Aging 1995; 6: 421–5

    CAS  PubMed  Google Scholar 

  8. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355–8

    CAS  PubMed  Google Scholar 

  9. Caradoc-Davies TH. Nonsteroidal anti-inflammatory drugs, arthritis, and gastrointestinal bleeding in elderly patients. Age Ageing 1984; 13: 295–8

    CAS  PubMed  Google Scholar 

  10. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 11: 359–63

    Google Scholar 

  11. Schlegel SI, Paulus HE. Nonsteroidal and analgesic therapy in the elderly. Clinics Rheum Dis 1986; 12: 245–73

    CAS  Google Scholar 

  12. Walt R, Katschinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; I: 489–92

    Google Scholar 

  13. Hughes GRV. The problem of using NSAIDs in the elderly. Scand J Rheumatol 1991; 91 Suppl.: 19–25

    CAS  Google Scholar 

  14. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (part I). Drugs Aging 1991; 1: 130–43

    CAS  PubMed  Google Scholar 

  15. Weinblatt ME. Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly. Scand J Rheumatol 1991; 91 Suppl.: 9–17

    CAS  Google Scholar 

  16. Jones AC, Berman P, Doherty M. Nonsteroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol 1992; 31: 45–8

    CAS  PubMed  Google Scholar 

  17. Prichard PJ, Kitchingma GK, Walt RP. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ 1989; 298: 493–6

    CAS  PubMed  Google Scholar 

  18. Leivonen M, Sipponen P, Kivilaakso E. Gastric changes in coronary-operated patients with low dose aspirin. Scand J Gastroenterol 1992; 27: 912–6

    CAS  PubMed  Google Scholar 

  19. Shorrock CJ, Langman MJS, Warlow C. Risks of upper GI bleeding during TIA prophylaxis with aspirin [abstract]. Gastroenterology 1992; 102: A165

    Google Scholar 

  20. Trujillo MA, Hardiner S, Garewal S, et al. Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer: at what cost? Dig Dis Sci 1994; 39: 2260–6

    CAS  PubMed  Google Scholar 

  21. Duthie A, Nicholls A, Freeth M, et al. Fatal cholestatic jaundice in elderly patients taking benoxaprofen [letter]. BMJ 1982; 285: 62

    CAS  PubMed  Google Scholar 

  22. Taggart S, Alderdice JM. Fatal jaundice in elderly patients taking benoxaprofen. BMJ 1982; 284: 1372

    CAS  PubMed  Google Scholar 

  23. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32

    CAS  PubMed  Google Scholar 

  24. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988; 41: 35–45

    CAS  PubMed  Google Scholar 

  25. Soll AH, Winstein WM, Kurata J, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307–19

    CAS  PubMed  Google Scholar 

  26. Cryer B, Redfern JS, Goldschmiedt M, et al. Effects of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992; 102: 1118–23

    CAS  PubMed  Google Scholar 

  27. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647–55

    CAS  PubMed  Google Scholar 

  28. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109: 1173–80

    CAS  PubMed  Google Scholar 

  29. Wallace JL. Gastric ulceration: critical events at the leukocyte-endothelium interface. Can J Physiol Pharmacol 1993; 71: 98–102

    CAS  PubMed  Google Scholar 

  30. Andrews FJ, Malcontenti-Wilson C, O’Brien PE. Effect of nonsteroidal antiinflammatory drugs on LFA-1 and ICAM-1 expression in the gastric mucosa. Am J Physiol 1994; 266: 657–64

    Google Scholar 

  31. Cush JJ, Rothlein R, Lindley HB, et al. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098–102

    CAS  PubMed  Google Scholar 

  32. Lamy PP. Renal effects of nonsteroidal antiinflammatory drugs: heightened risk in the elderly? J Am Geriatr Soc 1986; 34: 361–7

    CAS  PubMed  Google Scholar 

  33. Blackshear JL, Davidman M, Stilmann MT. Identification of risk for renal insufficiency from nonsteroidal antiinflammatory drugs. Arch Intern Med 1983; 143: 1130–4

    CAS  PubMed  Google Scholar 

  34. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12

    CAS  PubMed  Google Scholar 

  35. Wilson TW, Frohlich JC, Carr K. Urinary prostaglandin E in patients with renal artery stenosis [letter]. Clin Res 1973; 21: 416

    Google Scholar 

  36. Mazanec DJ. Nonsteroidal anti-inflammatory drug therapy: clinical use in a high-risk group — the elderly. Cleve Clin J Med 1988; 55: 419–25

    CAS  PubMed  Google Scholar 

  37. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective. Drugs 1996; 51: 179–87

    PubMed  Google Scholar 

  38. Kent RS, Kitchell BB, Shand DG, et al. The ability of vascular tissue to produce prostacyclin decreases with age. Prostaglandins 1981; 21: 483–90

    CAS  PubMed  Google Scholar 

  39. Friedman PL, Brown Jr EJ, Gunther S, et al. Coronary vasoconstrictor effect of indomethacin in patents with coronary artery disease. N Engl J Med 1981; 305: 1171–5

    CAS  PubMed  Google Scholar 

  40. Van den Ouweland FA, Gribnau FW, Meyboom RHB. Congestive heart failure due to nonsteroidal antiinflammatory drugs in the elderly. Age Ageing 1988; 17: 8–16

    PubMed  Google Scholar 

  41. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25: 1013–5

    CAS  PubMed  Google Scholar 

  42. Woodhouse KW, Wynne H. The pharmacokinetics of nonsteroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet 1987; 12: 111–2

    CAS  PubMed  Google Scholar 

  43. Kean WF, Buchanan WW. Variables affecting the absorption of nonsteroidal anti-inflammatory drugs from the gastrointestinal tract. Jpn J Rheumatol 1987; 1: 227–44

    Google Scholar 

  44. Anne AP, Halpen SM, Streete PJ, et al. Slow release aspirin in the elderly. J R Soc Med 1994; 87: 183–4

    Google Scholar 

  45. Reidenberg MM. Drugs in the elderly. Bull N Y Acad Med 1980; 56: 703–14

    CAS  PubMed  Google Scholar 

  46. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. Med Intell 1989; 321: 303–9

    CAS  Google Scholar 

  47. Tollesfsbol TO, Cohen JH. Role of protein molecular and metabolic aberrations in aging, in the physiologic decline of the aged, and in age-associated diseases. J Am Geriatr Soc 1986; 34: 282–94

    Google Scholar 

  48. Wallace SM, Verbeek RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987; 12: 41–72

    CAS  PubMed  Google Scholar 

  49. Murray MD, Brater DC. Nonsteroidal anti-inflammatory drugs. Clin Geriatr Med 1989; 6: 365–97

    Google Scholar 

  50. Verbeek RK. Pharmacokinetics of drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990; 19: 44–66

    Google Scholar 

  51. Buchanan WW, Kean WF. Implications of antirheumatic drug therapy in elderly patients with osteoarthritis. J Rheumatol 1978; 14: 98–100

    Google Scholar 

  52. Richardson CJ, Blocka KLN, Ross SG, et al. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985; 37: 13–8

    CAS  PubMed  Google Scholar 

  53. Arnoff GR, Ozawa T, De Sante KA, et al. Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther 1982; 32: 190–4

    Google Scholar 

  54. Woodhouse K. Drugs and the aging gut, liver and pancreas. Clin Gastroenterol 1985; 14: 863–81

    CAS  PubMed  Google Scholar 

  55. Kelly JG, McGarry K, O’Malley K, et al. Bioavailability of labetalol increases with age. Br J Clin Pharmacol 1982; 14: 304–5

    CAS  PubMed  Google Scholar 

  56. Piquette-Miller M, Jamali F. Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions 1992; 37: 290–6

    CAS  PubMed  Google Scholar 

  57. Piquette-Miller M, Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos 1995; 23: 240–5

    CAS  PubMed  Google Scholar 

  58. Meffin PJ. The effects of renal dysfunction on the disposition of NSAIDs forming acyl-glucuronides. Agents Actions 1985; 17: 85–9

    CAS  Google Scholar 

  59. Verbeek RK. Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal anti-inflammatory drugs. J Rheumatol 1988; 17: 44–57

    Google Scholar 

  60. Ritch AES, Perera WNR, Jones CJ. Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol 1982; 14: 116–9

    CAS  PubMed  Google Scholar 

  61. Traeger A, Kunze M, Sten G, et al. Pharmacokinetics of indomethacin in the aged. Z Alternsforsch 1973; 27: 151–5

    CAS  PubMed  Google Scholar 

  62. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5

    CAS  PubMed  Google Scholar 

  63. Wallace JL, Tigley AW. New insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther 1995; 9: 227–35

    CAS  PubMed  Google Scholar 

  64. Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid anti-rheumatoid drugs. Arch Toxicol 1984; 7: 315–22

    CAS  Google Scholar 

  65. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610–4

    CAS  PubMed  Google Scholar 

  66. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthetase in inflammation. Proc Natl Acad Sci U S A 1994; 91: 2046–50

    CAS  PubMed  Google Scholar 

  67. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371–86

    CAS  PubMed  Google Scholar 

  68. Wallace JL. Mechanisms of non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal damage: potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994; 72: 1493–7

    CAS  PubMed  Google Scholar 

  69. Ehrlich GE, Katz WA, Cohen SA. Rheumatoid arthritis in the aged. Geriatrics 1970; 25: 103–13

    CAS  PubMed  Google Scholar 

  70. Nesher G, Moore TL, Zucker J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991; 39: 284–94

    CAS  PubMed  Google Scholar 

  71. Magaro M, Altamonte L, Zoli A, et al. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with nonsteroidal anti-inflammatory drugs. Panminerva Med 1989; 31: 16–8

    CAS  PubMed  Google Scholar 

  72. Sano HT, Hla JAM, Maier LJ, et al. In vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89: 97–108

    CAS  PubMed  Google Scholar 

  73. Szcepanski A, Moatter T, Carley WW, et al. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1: inhibition by glucocorticoids. Arthritis Rheum 1994; 37: 495–503

    Google Scholar 

  74. Crofford LJ, Wilder RL, Ristimalki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 1994; 93: 1095–101

    CAS  PubMed  Google Scholar 

  75. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180–7

    CAS  PubMed  Google Scholar 

  76. Wong S, Lee SJ, Frierson MRI, et al. Antiarthritic profile of BF-389, a novel antiinflammatory agent with low ulcerogenic liability. Agents Actions 1992; 37: 90–8

    CAS  PubMed  Google Scholar 

  77. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects which cause minimal stomach lesions. Gen Pharmacol 1993; 24: 105–10

    CAS  PubMed  Google Scholar 

  78. Boyce S, Chan CC, Gordon R, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology 1994; 33: 1609–11

    CAS  PubMed  Google Scholar 

  79. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228–32

    CAS  PubMed  Google Scholar 

  80. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013–7

    CAS  PubMed  Google Scholar 

  81. Tagari P, Pannetin M, Ragori R. Assessment of NSAID gastroenteropathy in primates [abstract]. Can J Physiol Pharmacol 1994; 7: 267

    Google Scholar 

  82. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclooxygenase (COX-2): a safer therapeutic target? Br J Rheumatol 1994; 33: 410–1

    CAS  PubMed  Google Scholar 

  83. Dingle JT. Prostaglandins in human cartilage metabolism. J Lipid Mediat 1993; 6: 303–12

    CAS  PubMed  Google Scholar 

  84. Milner JC. Osteoarthritis of the hip and indomethacin [abstract]. J Bone Joint Surg 1971; 54B: 752

    Google Scholar 

  85. Ronningen H, Langeland N. Indomethacin treatment in osteoarthritis of the hip joint. Acta Orthop Scand 1979; 50: 169–74

    CAS  PubMed  Google Scholar 

  86. Brooks PM, Potter SR, Buchanan WW. NSAID and osteoarthritis: help or hindrance? J Rheumatol 1982; 9: 3–4

    CAS  PubMed  Google Scholar 

  87. Dingle JT. The interactions of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair. Adv Prostaglandin Thromboxane Leukot Res 1990; 21: 955–65

    Google Scholar 

  88. Dingle JT. Cartilage maintenance in osteoarthritis: interaction of cytokines, NSAIDs and prostaglandins in articular cartilage and repair. J Rheumatol 1991; 18 Suppl. 28: 30–7

    Google Scholar 

  89. Willoughby DA, Colville-Nash PR, Seed MD. Inflammation, prostaglandins, and loss of function. J Lipid Mediat 1993; 6: 287–93

    CAS  PubMed  Google Scholar 

  90. Rashad S, Reuell P, Hemingway A, et al. Effect of nonsteroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; II: 519–22

    Google Scholar 

  91. Onoe Y, Miyaura C, Kaminakayashiki T, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156: 758–64

    CAS  PubMed  Google Scholar 

  92. Sato T, Morita I, Sakaguchi K, et al. Involvement of cyclooxygenase-2 in bone loss induced by interleukin-1. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 445–7

    CAS  PubMed  Google Scholar 

  93. Harris RC, McKanna JA, Jacobson HR, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504–10

    CAS  PubMed  Google Scholar 

  94. Dunn MJ, Staley RS, Harison M. Characterization of prostaglandin production in tissue culture of rat renal medullary cells. Prostaglandins 1976; 12: 37–49

    CAS  PubMed  Google Scholar 

  95. Persson AEG, Salomonsson M, Westerlund P. Macula densa cell function. Kidney Int 1991; 39 Suppl. 32: S39–44

    Google Scholar 

  96. Lagenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483–92

    Google Scholar 

  97. Morham SG, Langenbach RL, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473–82

    CAS  PubMed  Google Scholar 

  98. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406–9

    CAS  PubMed  Google Scholar 

  99. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861–8

    CAS  PubMed  Google Scholar 

  100. Wallace JL, Cirino G. The development of gastrointestinal sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994; 15: 405–6

    CAS  PubMed  Google Scholar 

  101. Graham DY, Malatry HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495–501

    CAS  PubMed  Google Scholar 

  102. Katelaris PH, Seow F, Lin BP, et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin acid secretion in healthy men. Gut 1993; 34: 11032–7

    Google Scholar 

  103. Safe AF, Warren B, Corfield A, et al. Helicobacter pylori infection in elderly people: correlation between histology and serology. Age Ageing 1993; 22: 215–20

    CAS  PubMed  Google Scholar 

  104. Veldhuyzen van Zanten SJ, Pollack PT, Best LM, et al. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994; 169: 434–7

    CAS  PubMed  Google Scholar 

  105. Buckley M, Martin P, O’Morain C. Helicobacter pylori infection: implications for ulcer therapy in older patients. Drugs Aging 1994; 5: 1–7

    CAS  PubMed  Google Scholar 

  106. Gebbers JO, Otto HF. Ulcerative colitis in the elderly. Lancet 1975; II: 714–5

    Google Scholar 

  107. Levitan R. GI problems in the elderly: part II. Prevalent diseases and disorders. Geriatrics 1989; 44: 80–6

    CAS  PubMed  Google Scholar 

  108. Kaufman HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–5

    Google Scholar 

  109. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38: 1311–21

    CAS  PubMed  Google Scholar 

  110. Fitzgerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B–5B

    CAS  PubMed  Google Scholar 

  111. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304–12

    CAS  PubMed  Google Scholar 

  112. Wallace JL, McKnight W, Del Soldato P, et al. Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995; 96: 2711–8

    CAS  PubMed  Google Scholar 

  113. Tanaka A, Saki H, Motoyama Y, et al. Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis: evaluation and synthesis of 4,5-bis (4-methoxyphenyl)-2-substituted thiazoles. J Med Chem 1994; 37: 1189–99

    CAS  PubMed  Google Scholar 

  114. Davis AE, Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med 1994; 24: 301–3

    CAS  PubMed  Google Scholar 

  115. Rao CV, Riverson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464–72

    CAS  PubMed  Google Scholar 

  116. Craven PA, Saito R, DeRubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983; 72: 1365–75

    CAS  PubMed  Google Scholar 

  117. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1978; 272: 634–6

    CAS  PubMed  Google Scholar 

  118. Lynch NR, Castes M, Astoin M, et al. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 1978; 38: 503–12

    CAS  PubMed  Google Scholar 

  119. Eberhardt CE, Coffey RJ, Radhika A, et al. Up regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8

    Google Scholar 

  120. Kargman SL, O’Neill GP, Vikers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colorectal cancer. Cancer Res 1991; 55: 2556–9

    Google Scholar 

  121. Ryseck RP, Raynoschek C, Macdonald-Bravo H, et al. Identification of an immediate early gene, PGHS B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ 1993; 3: 443–50

    Google Scholar 

  122. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049–54

    CAS  PubMed  Google Scholar 

  123. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and in inducible forms of human cyclo-oxygenase. Biochem J 1995; 305: 479–84

    CAS  PubMed  Google Scholar 

  124. Rochon PA, Fortin PR, Dear KBG, et al. Reporting of age data in clinical trials of arthritis. Arch Intern Med 1993; 153: 243–8

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

    Neal M. Davies

  2. Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada

    John L. Wallace

Authors
  1. Neal M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John L. Wallace
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John L. Wallace.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, N.M., Wallace, J.L. Selective Inhibitors of Cyclooxygenase-2. Drugs & Aging 9, 406–417 (1996). https://doi.org/10.2165/00002512-199609060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609060-00004

Keywords

Search

Navigation